🔗 Share this article

As America proceeds with sweeping changes to its vaccination recommendations, one figure has emerged in a surprising turn: Dr. Tracy Beth Høeg, a Danish American physician and public health researcher who first made her name by casting doubt on COVID-19 vaccinations throughout the pandemic and has concentrated on alleged deaths after COVID-19 immunization in her short tenure at the US Food and Drug Administration (FDA).

Planned Shifts to Pediatric Immunization Program

Agency leaders had intended to announce sweeping revisions to the pediatric vaccine schedule recently, bringing the US with the Danish vaccine program, it is understood – a significant shift that would put the US out of step with much of the world with insufficient data for improved outcomes. The planned update has been delayed until the new year.

Instead of the top vaccines chief, Høeg is scheduled to present at the meeting. She was just designated temporary leader of the FDA’s drug evaluation center, the fifth individual to lead the division this calendar year.

A Shift at the FDA

The acting appointment might represent a strengthened alliance between the pharmaceutical and vaccine branches as Høeg and Prasad strengthen their influence at the agency – and it points to a increased emphasis upon dismantling long-standing vaccines at the FDA.

The new acting director has frequently advocated for ending some pediatric immunization guidelines in the US in order to be more in line with the Danish model, a country with comprehensive healthcare and a number of inhabitants about the population of Wisconsin’s.

So far public appearances, she has kept her attention on vaccines – usually the responsibility of Prasad, head of the FDA’s CBER – as opposed to drug regulation.

Questions Over Background

Dr. Høeg has no apparent background in pharmaceutical research, approval processes or leadership, which has been customary for past directors of the Center for Biologics Evaluation and Research. She has served at the FDA as a key advisor to the FDA chief and the vaccine center since March.

“It seems she lacks to have any of the qualifications” for overseeing the drug-regulation department, said Dr. Jonathan Howard. “She lacks experience running a scientific study. She is not versed in running a sizeable institution. She has no expertise in pharmaceutical oversight.”

Former heads of CBER would “grasp legal statutes and the underlying principles of medication creation”, commented Dr. Janet Woodcock. “Objectively, she has not acquired the sort of resume that prior appointees who led the center have had.”

This division has an enormous workload at the agency, she emphasized.

“Everybody just zeroes in on the innovative therapies, but the off-patent medication office authorizes numerous generic drugs. There is also a biologic copycat branch, non-prescription drug unit and other areas, and every single one must be looked after,” she noted. “The thing you overlook, that is precisely what that I always told people is going to come back to haunt you.”

There is also, a substantial administrative element to the role, which manages over 5,000 staff members. “It’s a massive leadership role, if you perform it correctly,” she added.

Agency Reaction and Controversial Initiatives

Regarding inquiries about Høeg’s credentials and whether this selection represents more teamwork among FDA leaders on immunizations, a press secretary said that the “concerns rely on incorrect assumptions”.

“This background is consistent with the functions of her role,” the representative explained, noting the months Dr. Høeg spent guiding the agency head on “medication safety and approval science, including predictive safety algorithms and shot safety tracking”.

As the temporary head, Høeg assumes responsibility for the agency head's controversial priority voucher program, a contentious rapid therapy clearance system that allegedly troubled her predecessors. “How are these drugs being chosen for this voucher program? Who makes the decisions?” Dr. Howard said. “There’s a lot of lack of transparency occurring at the regulatory body right now.”

In general, he remarked, “the Food and Drug Administration looks to be trending towards less stringent rules of all drugs, with the exception of vaccines.”

Established Track Record on Immunizations

Concerning immunizations, Dr. Høeg has a more documented, if concerning, past, Howard have noted. She authored a study using non-validated crowd-sourced reports to determine the incidence of heart inflammation following COVID-19 immunization. She consulted for the state of Florida chief medical officer Joseph Ladapo, who reportedly have changed statistics to suggest COVID-19 vaccinations are more dangerous than they are.

Included in her “policy goals” for the current government encompassed changing guidelines for recently developed shots and halting “non-essential” vaccines, she said post-election on a audio program. At the agency, Høeg has allegedly suggested barring adolescent males from obtaining COVID-19 vaccines.

“She’s an thorough dogmatist who commences with her preconceived notions and tailors the evidence to fit the evidence in a very deceptive, untruthful manner,” Dr. Howard said.

Gaining Influence and a “Campaign of Retribution”

Dr. Høeg aligned with fellow skeptics, {like|